Jump to main content.

Chloroprene Quickview (CASRN 126-99-8)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Chloroprene

File First On-Line: 09/30/2010; Last Significant Revision: 09/30/2010

Category (section)
Last Revised
Oral RfD Assessment Message 09/30/2010
Inhalation RfC Assessment Yes 09/30/2010
Carcinogenicity Assessment Yes 09/30/2010
  • 2-chlorobuta-1,3-diene
  • 2-chloro-1,3-butadiene
  • chlorobutadiene
  • 2-chlorobutadiene
  • 2-chlorobutadiene-1,3
  • beta-chloroprene
  • chloroprene
  • 126-99-8
Chloroprene Source Documents
Revision History
Date Section Description
09/30/2010 I, II, VI, VII, VIII RfC, and cancer assessment added
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Information reviewed but value not estimated. See IRIS Summary.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively BMDL (HEC): 2 mg/m3 100 2x10-2 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • Likely to be carcinogenic to humans
  • Weight-of-Evidence Narrative:
    • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is evidence that chloroprene is "likely to be carcinogenic to humans"
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Information reviewed but value not estimated. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)
Extrapolation Method
3 x10-4 per µg/m3 Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
  • Dose-Response Data (Carcinogenicity, Inhalation Exposure)
    • Tumor Type: alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma
    • Test Species: female B6C3F1 mice
    • Route: Inhalation
    • Reference: NTP, 1998

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.